Evotec SE (LON:0IRF)

Market Cap	947.93M
Revenue (ttm)	666.32M
Net Income (ttm)	-133.32M
Shares Out	n/a
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,398
Average Volume	82,343
Open	5.85
Previous Close	5.84
Day's Range	5.85 - 6.00
52-Week Range	5.06 - 10.61
Beta	1.06
RSI	50.05
Earnings Date	Nov 5, 2025

About Evotec SE

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic disease...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1993
• Employees: 4,740
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0IRF

Financial Performance

In 2024, Evotec SE's revenue was 796.97 million, an increase of 1.99% compared to the previous year's 781.43 million. Losses were -196.08 million, 133.7% more than in 2023.

Financial numbers in EUR